2.2× less narcotic use
Treated patients used roughly half the opioids over the first 48 hours (p = 0.002).
The finding
In Rhode 2010, patients using the active device consumed roughly half the narcotics over the first 48 hours — about 5 oxycodone-equivalent pills versus 11 in the sham group, a 2.2-fold difference (p = 0.002). This is the single most consequential result in the trial.
Why opioid-sparing is the headline
Post-operative prescriptions are a recognized on-ramp to long-term opioid use, and tens of thousands of opioid deaths each year begin with a legitimate script. A non-drug adjunct that cuts early narcotic demand roughly in half — with no side effects of its own — is valuable to the patient, the surgeon, and the payer at the same time.
The study design
Narcotic consumption was tracked as opioid-equivalent dosing (morphine milligram equivalents, converted from oxycodone and other agents used). Patients had unrestricted access to rescue narcotics — they were not rationed. The 2.2-fold difference therefore reflects genuine reduced analgesic need, not restricted access. The p-value of 0.002 means there is less than a 0.2% probability the observed difference arose by chance. This was a pre-specified endpoint, not a post-hoc finding.
What this means in practice
Six fewer opioid-equivalent pills in 48 hours is not primarily a comfort number — it is an exposure number. Each opioid pill carries risks: nausea (affecting mobility and nutrition), sedation (affecting respiratory clearance), constipation (affecting hospital length of stay), and a measurable increase in long-term dependence risk. A patient who takes 5 pills rather than 11 in the first two days goes home with a smaller prescription, fewer pills in the home, and a lower probability that their post-surgical opioid use becomes a long-term pattern.
Compared to the standard alternative
Multimodal analgesia — the standard approach combining NSAIDs, acetaminophen, local anesthetic blocks, and opioids as needed — reduces but does not eliminate opioid use. The Rhode 2010 active patients were already receiving standard multimodal care; the 2.2× reduction was on top of that baseline. Adding tPEMF to an existing multimodal protocol does not replace any component — it further reduces the opioid contribution within the bundle.
Sources
- Rhode C, et al. Plast Reconstr Surg. 2010 — narcotic consumption (p = 0.002)
Related
Ready to put SofPulse to work?
SofPulse is available by prescription. Patients can order online and pay with pre-tax HSA/FSA dollars; clinicians can start prescribing in minutes.
For education only — not medical advice, and not a substitute for a clinician's judgment. SofPulse is available by prescription only. Reimbursement figures reflect the 2026 CMS Physician Fee Schedule and vary by locality, payer, and documentation.